Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hillengass

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Der Radiologe|January 18, 2022
[Science and reality]S Delorme, J Hillengass
Der Radiologe|March 24, 2012
[Multiple myeloma: current recommendations for imaging]J Hillengass, S Delorme
Current Pharmaceutical Biotechnology|December 16, 2006
Thalidomide in multiple myelomaT M Moehler, J Hillengass, A Glasmacher, et al.
Current Pharmaceutical Design|April 14, 2004
Antiangiogenic therapy in hematologic malignanciesT M Moehler, J Hillengass, H Goldschmidt, et al.
International Journal of Hematology|October 11, 2008
Clinical evidence for immunomodulation induced by high-dose melphalan and autologous blood stem cell transplantation as cause for complete clinical remission of multiple myeloma-associated cryoglobulin-vasculitisJ Hillengass, A D Ho, H Goldschmidt, et al.
Oncoimmunology|October 25, 2019
Alternative metrics for assessing clinical benefit with immunotherapy in oncologyE Chan, C Quinn, I Hirji, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 31, 2016
Treatment response evaluation with <sup>18</sup>F-FDG PET/CT and <sup>18</sup>F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantationChristos Sachpekidis, J Hillengass, H Goldschmidt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2001
High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myelomaK Neben, T Moehler, G Egerer, et al.
Der Radiologe|September 15, 2017
[Focal lesions in whole-body MRI in multiple myeloma : Quantification of tumor mass and correlation with disease-related parameters and prognosis]S C Brandelik, J Krzykalla, T Hielscher, et al.
Transfusion Medicine (Oxford, England)|October 12, 2016
Performance assessment and benchmarking of autologous peripheral blood stem cell collection with two different apheresis devicesP Wuchter, M Hundemer, A Schmitt, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Der Radiologe|January 18, 2022
[Science and reality]S Delorme, J Hillengass
Der Radiologe|March 24, 2012
[Multiple myeloma: current recommendations for imaging]J Hillengass, S Delorme
Current Pharmaceutical Biotechnology|December 16, 2006
Thalidomide in multiple myelomaT M Moehler, J Hillengass, A Glasmacher, et al.
Current Pharmaceutical Design|April 14, 2004
Antiangiogenic therapy in hematologic malignanciesT M Moehler, J Hillengass, H Goldschmidt, et al.
International Journal of Hematology|October 11, 2008
Clinical evidence for immunomodulation induced by high-dose melphalan and autologous blood stem cell transplantation as cause for complete clinical remission of multiple myeloma-associated cryoglobulin-vasculitisJ Hillengass, A D Ho, H Goldschmidt, et al.
Oncoimmunology|October 25, 2019
Alternative metrics for assessing clinical benefit with immunotherapy in oncologyE Chan, C Quinn, I Hirji, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 31, 2016
Treatment response evaluation with <sup>18</sup>F-FDG PET/CT and <sup>18</sup>F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantationChristos Sachpekidis, J Hillengass, H Goldschmidt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2001
High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myelomaK Neben, T Moehler, G Egerer, et al.
Der Radiologe|September 15, 2017
[Focal lesions in whole-body MRI in multiple myeloma : Quantification of tumor mass and correlation with disease-related parameters and prognosis]S C Brandelik, J Krzykalla, T Hielscher, et al.
Transfusion Medicine (Oxford, England)|October 12, 2016
Performance assessment and benchmarking of autologous peripheral blood stem cell collection with two different apheresis devicesP Wuchter, M Hundemer, A Schmitt, et al.
Pageof 3